We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DVA & Humana Expand Value-Based Care for Kidney Disease Patients
Read MoreHide Full Article
Key Takeaways
DaVita expands value-based kidney care to over 10,000 Humana members with CKD stages 3B???5.
The program targets earlier intervention to slow kidney disease progression and reduce hospitalizations.
DaVita IKC coordinates whole-person care through teams addressing clinical and nonclinical patient needs.
DaVita (DVA - Free Report) recently announced a new value-based care agreement with Humana to provide comprehensive, coordinated care to more than 10,000 Humana Medicare Advantage members with chronic kidney disease (CKD) stages 3B–5. The program, which began on July 1, expands on the companies’ existing collaboration in end-stage kidney disease to earlier stages of CKD, where timely intervention may help delay disease progression and reduce hospitalizations.
Per management, kidney care is undergoing a therapeutic revolution, with upstream interventions helping to reshape patient outcomes. Through the partnership with Humana, DaVita is deploying advanced care that treats the whole patient, helps preserve kidney function and serves as a central hub for managing comorbid conditions that affect kidney health.
DVA Stock Trend Following the News
Following the announcement, shares of DVA inched up 0.7% at yesterday’s close. Year to date, the stock has surged 56.5% compared with the industry’s 23.6% growth and the S&P 500’s 11.4% rise.
The expanded partnership with Humana is a positive development for DaVita as it strengthens the company’s presence in value-based kidney care and broadens its role beyond end-stage kidney disease management. Serving more than 10,000 additional patients could support greater engagement in earlier-stage CKD while creating opportunities to improve clinical outcomes and reduce costly hospitalizations. Over time, successful execution of the model could reinforce DaVita’s value-based care capabilities and support further partnerships with health plans.
DVA currently has a market capitalization of $11.26 billion.
Image Source: Zacks Investment Research
More on the News
The program focuses on CKD patients at stages 3B–5, a critical point when kidney function may decline rapidly but the condition can remain underdiagnosed or undertreated. Through DaVita Integrated Kidney Care (DaVita IKC), the company provides coordinated, whole-person care that addresses the close links between kidney, cardiovascular and metabolic health, with the goal of reducing care gaps and preventing avoidable hospitalizations.
The program builds on DaVita’s network of approximately 3,000 value-based nephrologist partners. Patients receive support from an interdisciplinary care team designed to address clinical and nonclinical barriers, including nutrition, transportation and mental health needs. The value-based model also provides education and advance care planning for patients who progress toward kidney failure, including guidance on home dialysis and kidney transplantation.
By bringing these services together, DaVita aims to stabilize kidney function, slow disease progression and create a smoother transition between stages of care. The expanded partnership reflects the growing focus on value-based, preventive care and DaVita’s strategy of intervening earlier to better manage complex kidney disease and improve outcomes.
Industry Prospects Favoring the Market
Going by data provided by Global Market Insights, the U.S. dialysis services market is predicted to be valued at $37.7 billion in 2026 and is expected to witness a CAGR of 3.5% through 2035.
Factors such as the rising number of end-stage renal disease patients, increasing incidence of diabetes leading to kidney disorders, favorable reimbursement scenario available for dialysis treatment and expansion of dialysis centers across the United States are expected to support market growth.
Other News
Recently, DaVita exited the second quarter of 2026, wherein both earnings and revenues surpassed the estimates. Revenue per treatment was up year over year, but down sequentially. Solid revenues from both Dialysis patient service and Other sources, higher U.S. dialysis treatments per day and an uptick in normalized non-acquired treatment were encouraging. Management highlighted plans to expand hemodialysis across its network once an adequate supply of newly approved dialyzers is secured. Compatible with existing machines, the technology can broaden patient access without significant capital investment and may improve clinical outcomes, with mortality-related economic benefits expected from 2028.
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
DVA & Humana Expand Value-Based Care for Kidney Disease Patients
Key Takeaways
DaVita (DVA - Free Report) recently announced a new value-based care agreement with Humana to provide comprehensive, coordinated care to more than 10,000 Humana Medicare Advantage members with chronic kidney disease (CKD) stages 3B–5. The program, which began on July 1, expands on the companies’ existing collaboration in end-stage kidney disease to earlier stages of CKD, where timely intervention may help delay disease progression and reduce hospitalizations.
Per management, kidney care is undergoing a therapeutic revolution, with upstream interventions helping to reshape patient outcomes. Through the partnership with Humana, DaVita is deploying advanced care that treats the whole patient, helps preserve kidney function and serves as a central hub for managing comorbid conditions that affect kidney health.
DVA Stock Trend Following the News
Following the announcement, shares of DVA inched up 0.7% at yesterday’s close. Year to date, the stock has surged 56.5% compared with the industry’s 23.6% growth and the S&P 500’s 11.4% rise.
The expanded partnership with Humana is a positive development for DaVita as it strengthens the company’s presence in value-based kidney care and broadens its role beyond end-stage kidney disease management. Serving more than 10,000 additional patients could support greater engagement in earlier-stage CKD while creating opportunities to improve clinical outcomes and reduce costly hospitalizations. Over time, successful execution of the model could reinforce DaVita’s value-based care capabilities and support further partnerships with health plans.
DVA currently has a market capitalization of $11.26 billion.
Image Source: Zacks Investment Research
More on the News
The program focuses on CKD patients at stages 3B–5, a critical point when kidney function may decline rapidly but the condition can remain underdiagnosed or undertreated. Through DaVita Integrated Kidney Care (DaVita IKC), the company provides coordinated, whole-person care that addresses the close links between kidney, cardiovascular and metabolic health, with the goal of reducing care gaps and preventing avoidable hospitalizations.
The program builds on DaVita’s network of approximately 3,000 value-based nephrologist partners. Patients receive support from an interdisciplinary care team designed to address clinical and nonclinical barriers, including nutrition, transportation and mental health needs. The value-based model also provides education and advance care planning for patients who progress toward kidney failure, including guidance on home dialysis and kidney transplantation.
By bringing these services together, DaVita aims to stabilize kidney function, slow disease progression and create a smoother transition between stages of care. The expanded partnership reflects the growing focus on value-based, preventive care and DaVita’s strategy of intervening earlier to better manage complex kidney disease and improve outcomes.
Industry Prospects Favoring the Market
Going by data provided by Global Market Insights, the U.S. dialysis services market is predicted to be valued at $37.7 billion in 2026 and is expected to witness a CAGR of 3.5% through 2035.
Factors such as the rising number of end-stage renal disease patients, increasing incidence of diabetes leading to kidney disorders, favorable reimbursement scenario available for dialysis treatment and expansion of dialysis centers across the United States are expected to support market growth.
Other News
Recently, DaVita exited the second quarter of 2026, wherein both earnings and revenues surpassed the estimates. Revenue per treatment was up year over year, but down sequentially. Solid revenues from both Dialysis patient service and Other sources, higher U.S. dialysis treatments per day and an uptick in normalized non-acquired treatment were encouraging. Management highlighted plans to expand hemodialysis across its network once an adequate supply of newly approved dialyzers is secured. Compatible with existing machines, the technology can broaden patient access without significant capital investment and may improve clinical outcomes, with mortality-related economic benefits expected from 2028.
DaVita Inc. Price
DaVita Inc. price | DaVita Inc. Quote
DVA’s Zacks Rank & Key Picks
Currently, DVA carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.